BridgeMD
Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer
EU CTIS ID: 2025-522431-34-00
What this study is testing
To compare the efficacy of molecularly tailored therapy versus standard of care in patients with pancreatic cancer with actionable reimbursed druggable molecular alterations as measured by progression-free survival
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (aged 18 and over)
- Pancreatic cancer confirmed by cytology or histology
- Written informed consent before any specific study procedures
- Available personalized report communicating the molecular testing results and detailed treatment options
- Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment
- ECOG Performance Status 0-2
You likely can't join if
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- Allergies and Adverse Drug Reaction - History of allergy to study drug components - Hypersensitivity to the active substances
- WOCBP who are pregnant or breastfeeding
See the full eligibility criteria
- Adult patients (aged 18 and over)
- Pancreatic cancer confirmed by cytology or histology
- Written informed consent before any specific study procedures
- Available personalized report communicating the molecular testing results and detailed treatment options
- Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment
- ECOG Performance Status 0-2
- Participants must have normal organ and marrow function as defined below: - Absolute neutrophil count ≥ 1.5 x 10⁹/L - Platelet count ≥ 75 x 10⁹/L - Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) - AST/ALT ≤ 5 x ULN - Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (using the Cockcroft-Gault formula)
- Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in the protocol
- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- Allergies and Adverse Drug Reaction - History of allergy to study drug components - Hypersensitivity to the active substances
- WOCBP who are pregnant or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.